Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27966884 | 0.77 | RAB9A (0.39) | ALDH1A1HPGDRAB9ASMN1; SMN2LMNA | |
| SCHEMBL6092122 | 0.73 | HCRTR1 (0.39) | ALDH1A1RAB9ASMN1; SMN2MYC | |
| SCHEMBL6092495 | 0.69 | L3MBTL1 (0.42) | ALDH1A1RAB9AKMT2A | |
| SCHEMBL3975555 | 0.69 | ALDH1A1 (0.48) | ALDH1A1MAPTMAOBLMNAMEN1 | |
| SCHEMBL23967931 | 0.67 | TSHR (0.41) | ALDH1A1HPGDSMN1; SMN2HTTMYC | |
| SCHEMBL18606778 | 0.67 | TSHR (0.41) | ALDH1A1HPGDSMN1; SMN2HTTMYC | |
| SCHEMBL28027270 | 0.66 | HPGD (0.43) | ALDH1A1HPGDRAB9AMAOBSMN1; SMN2 | |
| SCHEMBL66979 | 0.65 | ALDH1A1 (0.52) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| Biphenyl SCHEMBL2455099 | 0.65 | ALDH1A1 (0.48) | ALDH1A1RAB9ALMNAMEN1KMT2A | |
| SCHEMBL27201517 | 0.65 | ALDH1A1 (0.51) | ALDH1A1HPGDMAPTRAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | ALDH1A1 159/4885HPGD 527/4885HSD17B10 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.